BRUKINSA在初治CLL患者中实现74%六年PFS里程碑
This data highlights BRUKINSA's sustained efficacy and durability in a challenging patient population.
BRUKINSA demonstrated 74% 6-year PFS in treatment-naïve CLL patients.
百济神州公布了一项III期研究的里程碑数据，显示BRUKINSA在初治慢性淋巴细胞白血病（CLL）患者中实现了六年74%的无进展生存率（PFS）。这一重要的长期疗效数据巩固了BRUKINSA作为CLL领先治疗选择的地位。
This data highlights BRUKINSA's sustained efficacy and durability in a challenging patient population. For APAC, where CLL is a significant concern, these results reinforce the value of BRUKINSA as a long-term treatment option, potentially improving patient outcomes and quality of life across the region.
BRUKINSA is a key product for BeiGene in APAC. Demonstrating such strong long-term efficacy in treatment-naïve CLL patients is highly relevant for oncologists and patients in the region, supporting its continued adoption and clinical use.
此信号在行业全局中的位置。
https://www.beigene.com/press-releases/brukinsa-delivers-landmark-74-percent-6-year-progression-free-survival-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia
阅读完整来源精选情报直达收件箱。无垃圾邮件，随时退订。
登录后可保存信号笔记。
登录